Announcement • Mar 10
Angiolab, Inc., Annual General Meeting, Mar 26, 2026 Angiolab, Inc., Annual General Meeting, Mar 26, 2026, at 11:00 Tokyo Standard Time. Location: conference room, 65, techno 3-ro, yuseong-gu, daejeon South Korea New Risk • Jan 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩7.96b market cap, or US$5.50m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). New Risk • Jul 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩13.2b market cap, or US$9.49m). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change). New Risk • Jun 17
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩13.5b (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩13.5b market cap, or US$9.86m). Announcement • Mar 08
Angiolab, Inc., Annual General Meeting, Mar 27, 2025 Angiolab, Inc., Annual General Meeting, Mar 27, 2025, at 11:00 Tokyo Standard Time. Location: conference room, 65, techno 3-ro, yuseong-gu, daejeon South Korea New Risk • Mar 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩20.4b market cap, or US$13.9m). Announcement • Feb 26
Angiolab, Inc. has completed a Follow-on Equity Offering in the amount of KRW 1 billion. Angiolab, Inc. has completed a Follow-on Equity Offering in the amount of KRW 1 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 125,000
Price\Range: KRW 8000
Transaction Features: Subsequent Direct Listing Announcement • Feb 12
Angiolab, Inc. has filed a Follow-on Equity Offering in the amount of KRW 1 billion. Angiolab, Inc. has filed a Follow-on Equity Offering in the amount of KRW 1 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 125,000
Price\Range: KRW 8000
Transaction Features: Subsequent Direct Listing New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩23.0b market cap, or US$15.8m). New Risk • Apr 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (₩17.3b market cap, or US$12.5m). New Risk • Mar 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 33% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩11.7b market cap, or US$8.76m). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). New Risk • Dec 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₩18.0b market cap, or US$13.8m). New Risk • Jun 22
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩12.6b (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (₩12.6b market cap, or US$9.74m). Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change). Announcement • Mar 12
Angiolab, Inc., Annual General Meeting, Mar 30, 2021 Angiolab, Inc., Annual General Meeting, Mar 30, 2021, at 11:00 Korea Standard Time. Is New 90 Day High Low • Jan 19
New 90-day high: ₩14,300 The company is up 59% from its price of ₩8,990 on 21 October 2020. The South Korean market is up 26% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 16% over the same period. Is New 90 Day High Low • Dec 29
New 90-day high: ₩11,800 The company is up 33% from its price of ₩8,900 on 29 September 2020. The South Korean market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period. Announcement • Sep 26
Hanyang Securities Co., Ltd., Investment Arm and Sun-Tae Kim acquired 2.9% stake in Angiolab, Inc. (XKON:A251280) from KB 12-1 Venture Fund of KB Investment Co., Ltd. for KRW 1.2 billion. Hanyang Securities Co., Ltd., Investment Arm and Sun-Tae Kim acquired 2.9% stake in Angiolab, Inc. (XKON:A251280) from KB 12-1 Venture Fund of KB Investment Co., Ltd. for KRW 1.2 billion on September 18, 2020. The offer per share is KR 12000. Hanyang Securities Co., Ltd., Investment Arm acquired 0.08 million shares while Sun-Tae Kim acquired 0.03 million shares of Angiolab.
Hanyang Securities Co., Ltd., Investment Arm and Sun-Tae Kim completed the acquisition of 2.9% stake in Angiolab, Inc. (XKON:A251280) from KB 12-1 Venture Fund of KB Investment Co., Ltd. on September 18, 2020. Announcement • Sep 19
Angiolab, Inc. (XKON:A251280) signed a contract to acquire NH Special Purpose Acquisition 13 Co., Ltd. (KOSDAQ:A310840) from BNK Venture Investment and others in a reverse merger transaction. Angiolab, Inc. (XKON:A251280) signed a contract to acquire NH Special Purpose Acquisition 13 Co., Ltd. (KOSDAQ:A310840) from BNK Venture Investment and others in a reverse merger transaction on June 29, 2020. merger ratio is NH Special Purpose Acquisition 13 Co., Ltd. : Angio Lab = 1: 7.6000000. When the merger of NH Special Purpose Acquisition 13 Co., Ltd. and AngioLab is completed, formally NH Special Purpose Acquisition 13 Co., Ltd. becomes a surviving corporation, and AngioLab becomes an extinction corporation. However, practically, AngioLab will be listed on the KOSDAQ market while maintaining business continuity. Shareholders meeting is scheduled for October 21, 2020. The deal is resolved by board on June 29, 2020. Date of merger is November 24, 2020. Scheduled merger registration date is November 26, 2020. Jeongin Accounting Corporation acted as evaluator for Angiolab, Inc. 
